Floatz logo

Immunoglobulin G4-Kappa, Anti-[Homo Sapiens Lgals3 (Galectin 3)], Humanized Monoclonal Antibody (Gamma4 Heavy Chain Humanized (1-442) [Vh (Homo Sapiens Ighv1-3*01 (88.7%) -(Ighd) -Ighj6*01 (93.3%), Cdr-Imgt [8.8.9] (26-33.51-58.97-105)) (1-116)-Homo Sapiens Ighg4*01, Ng4M(A) Ch2 L92, G4V5 H P10 (Ch1 (117-214), Hinge 1-12 S10>P (224)(215-226), Ch2 L92 (305) (227-336), Ch3 (337-441), Chs K2>Del (442)) (117-442)], (130-219')-Disulfide With Kappa Light Chain Humanized (1'-219') [V-Kappa(Homo Sapiens Igkv2D-29*02 (89.0%) -Igkj2*01(100%), Cdr-Imgt [11.3.9] (27-37.55-57.94-102)) (1'-112') -Homo Sapiens Igkc*01 (100%), Km3 A45.1(158), V101 (196) (113'-219')]; Dimer (222-222'':225-225'')-Bisdisulfide, Produced In Chinese Hamster Ovary (Cho) Cells, Glycoform Alfa)

Ischemic Stroke

Explore 198 assets in Ischemic Stroke →
Floatz Rating
CCC48/100
Confidence
Indicative
v0.2
Sponsor
TrueBinding, Inc.
Modality
monoclonal_antibody
Development Phase
Phase 2
Status
Active
Evidence ledger · v0.2

Clinical Evidence

Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
38Moderate confidence
Detailed axis rationale is planned and will be published soon.
TrialPhaseStatusNPrimary endpointReadout
NCT05156827CT.gov
A Study to Assess the Efficacy, Safety, and Pharmacokinetics of TB006 in Participants With Acute Ischemic Stroke
—Withdrawn———

Competitive Position

Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
65High confidence
Detailed axis rationale is planned and will be published soon.

Same indication · Ischemic Stroke

AssetSponsorPhaseRating
Immunoglobulin G4-Kappa, Anti-[Homo Sapiens Lgals3 (Galectin 3)], Humanized Monoclonal Antibody (Gamma4 Heavy Chain Humanized (1-442) [Vh (Homo Sapiens Ighv1-3*01 (88.7%) -(Ighd) -Ighj6*01 (93.3%), Cdr-Imgt [8.8.9] (26-33.51-58.97-105)) (1-116)-Homo Sapiens Ighg4*01, Ng4M(A) Ch2 L92, G4V5 H P10 (Ch1 (117-214), Hinge 1-12 S10>P (224)(215-226), Ch2 L92 (305) (227-336), Ch3 (337-441), Chs K2>Del (442)) (117-442)], (130-219')-Disulfide With Kappa Light Chain Humanized (1'-219') [V-Kappa(Homo Sapiens Igkv2D-29*02 (89.0%) -Igkj2*01(100%), Cdr-Imgt [11.3.9] (27-37.55-57.94-102)) (1'-112') -Homo Sapiens Igkc*01 (100%), Km3 A45.1(158), V101 (196) (113'-219')]; Dimer (222-222'':225-225'')-Bisdisulfide, Produced In Chinese Hamster Ovary (Cho) Cells, Glycoform Alfa) (this asset)TrueBinding, Inc.P2CCC · 48
TicagrelorSichuan Provincial People's HospitalP4BBB
CilostazolStanford UniversityP4BBB
Compound EdaravoneNanfang Hospital, Southern Medical UniversityP4BBB
TenecteplaseHackensack Meridian HealthP4BBB
ArgatrobanSecond Affiliated Hospital, School of Medicine, Zhejiang UniversityP4BBB
3-N-BUTYLPHTHALIDENanfang Hospital, Southern Medical UniversityP4BBB
ClopidogrelNanfang Hospital, Southern Medical UniversityP4BB
AspirinNanfang Hospital, Southern Medical UniversityP4BB

+42 more in the Ischemic Stroke cohort

Other indications for Immunoglobulin G4-Kappa, Anti-[Homo Sapiens Lgals3 (Galectin 3)], Humanized Monoclonal Antibody (Gamma4 Heavy Chain Humanized (1-442) [Vh (Homo Sapiens Ighv1-3*01 (88.7%) -(Ighd) -Ighj6*01 (93.3%), Cdr-Imgt [8.8.9] (26-33.51-58.97-105)) (1-116)-Homo Sapiens Ighg4*01, Ng4M(A) Ch2 L92, G4V5 H P10 (Ch1 (117-214), Hinge 1-12 S10>P (224)(215-226), Ch2 L92 (305) (227-336), Ch3 (337-441), Chs K2>Del (442)) (117-442)], (130-219')-Disulfide With Kappa Light Chain Humanized (1'-219') [V-Kappa(Homo Sapiens Igkv2D-29*02 (89.0%) -Igkj2*01(100%), Cdr-Imgt [11.3.9] (27-37.55-57.94-102)) (1'-112') -Homo Sapiens Igkc*01 (100%), Km3 A45.1(158), V101 (196) (113'-219')]; Dimer (222-222'':225-225'')-Bisdisulfide, Produced In Chinese Hamster Ovary (Cho) Cells, Glycoform Alfa)

IndicationSponsorPhaseRating
Alzheimer Disease—P2B · 58
Parkinson Disease—P2CCC · 53

Scientific Foundation

Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR

Planned for methodology v0.2.

Development Feasibility

How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR

Planned for methodology v0.2.

Commercial Opportunity

Commercial prize: addressable population, unmet need, and the value case for the indication.
NR

Planned for methodology v0.2.

IP & Exclusivity

Exclusivity position, covering patent protection and freedom-to-operate runway.
NR

Planned for methodology v0.2.

Manufacturing & Supply

Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR

Planned for methodology v0.2.

Related assets

Citation

Floatz Terminal. Immunoglobulin G4-Kappa, Anti-[Homo Sapiens Lgals3 (Galectin 3)], Humanized Monoclonal Antibody (Gamma4 Heavy Chain Humanized (1-442) [Vh (Homo Sapiens Ighv1-3*01 (88.7%) -(Ighd) -Ighj6*01 (93.3%), Cdr-Imgt [8.8.9] (26-33.51-58.97-105)) (1-116)-Homo Sapiens Ighg4*01, Ng4M(A) Ch2 L92, G4V5 H P10 (Ch1 (117-214), Hinge 1-12 S10>P (224)(215-226), Ch2 L92 (305) (227-336), Ch3 (337-441), Chs K2>Del (442)) (117-442)], (130-219')-Disulfide With Kappa Light Chain Humanized (1'-219') [V-Kappa(Homo Sapiens Igkv2D-29*02 (89.0%) -Igkj2*01(100%), Cdr-Imgt [11.3.9] (27-37.55-57.94-102)) (1'-112') -Homo Sapiens Igkc*01 (100%), Km3 A45.1(158), V101 (196) (113'-219')]; Dimer (222-222'':225-225'')-Bisdisulfide, Produced In Chinese Hamster Ovary (Cho) Cells, Glycoform Alfa) in Ischemic Stroke. Methodology v0.2.
Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026.
Accessed July 14, 2026.
https://terminal.floatz.ai/assets/immunoglobulin-g4-kappa-anti-homo-sapiens-lgals3-galectin-3-humanized-monoclonal-antibody-gamma4-heavy-chain-humanized-1-442-vh-homo-sapiens-ighv1-301-887-ighd-ighj601-933-cdr-imgt-889-26-3351-5897-105-1-116-homo-sapiens-ighg401-ng4ma-ch2-l92-g4v5-h-p10-ch1-117-214-hinge-1-12-s10p-224215-226-ch2-l92-305-227-336-ch3-337-441-chs-k2del-442-117-442-130-219-disulfide-with-kappa-light-chain-humanized-1-219-v-kappahomo-sapiens-igkv2d-2902-890-igkj201100-cdr-imgt-1139-27-3755-5794-102-1-112-homo-sapiens-igkc01-100-km3-a451158-v101-196-113-219-dimer-222-222225-225-bisdisulfide-produced-in-chinese-hamster-ovary-cho-cells-glycoform-alfa-ischemic-stroke

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →